The Profile of Glucose Lowering Therapy in Persons with Type 2 Diabetes Mellitus in an Aging Russian Population

We aimed to analyze the profile of glucose lowering therapy (GLT) in persons with diabetes mellitus type 2 (DM2) in an aging Russian population. A random population sample (n = 3898, men/women, 55−84) was examined in Novosibirsk, during 2015−2018 (HAPIEE Project). The design of the present work is a...

Full description

Saved in:
Bibliographic Details
Published in:Journal of personalized medicine 2022-10, Vol.12 (10), p.1689
Main Authors: Malyutina, Sofia, Mazurenko, Elena, Mazdorova, Ekaterina, Shapkina, Marina, Avdeeva, Ekaterina, Mustafina, Svetlana, Simonova, Galina, Ryabikov, Andrey
Format: Article
Language:English
Subjects:
Age
Aging
Antihypertensives
Blood pressure
Body mass index
Cardiovascular disease
Cholesterol
Diabetes
Diabetes mellitus (non-insulin dependent)
Drug therapy
Electrocardiography
Fasting
Glucose
Heart attacks
Hypertension
Insulin
Population
Precision medicine
Preventive medicine
Questionnaires
Sulfonylurea
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We aimed to analyze the profile of glucose lowering therapy (GLT) in persons with diabetes mellitus type 2 (DM2) in an aging Russian population. A random population sample (n = 3898, men/women, 55−84) was examined in Novosibirsk, during 2015−2018 (HAPIEE Project). The design of the present work is a cross-sectional study. DM2 was defined in those with a history of DM2 receiving GLT, or at a level of fasting plasma glucose (FPG) ≥7.0 mmol/L. The entire DM2 group was included in the analysis (n = 803); of these, 476 persons were taking GLT and were included in the analysis at stage 2. Regular GLT medication intake for 12 months was coded with ATC. In studied sample, the prevalence of DM2 was 20.8%. Among subjects with DM2, 59% of individuals received GLT, 32% did not. Glycemic control (FPG < 7.0 mmol/L) was achieved in every fifth participant with DM2 (35% in those receiving GLT). In frequency of GLT use, biguanides ranked in first place (75%), sulfonylurea derivatives in second (35%), insulins in third (12%), and iDPP-4 in fourth (5%). Among those receiving GLT, 24% used combined oral therapy, and 6% used insulin-combined therapy. In conclusion, in a population sample aged 55−84 examined in 2015−2018, glycemic control was achieved in every fifth participant with DM2, and in every third participant receiving GLT. The proportion of participants using new GLT drugs was small, and there was a lack of HbA1c monitoring for intensive glycemic control.
ISSN:2075-4426
2075-4426
DOI:10.3390/jpm12101689